Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance
AssigneeCity of Hope
InventorsWenYong Chen, Ravi Bhatia, Leila Su, Yate-Ching Yuan
Life of this patent
Estimating the term…
Abstract
A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.
Claims18
A culture model of chronic myelogenic leukemia (CML) acquired chemoresistant cells, the model generated by:
- contacting a blast crisis CML cell line, which has previously not been exposed to imatinab before, with a dose of imatinib sufficient to induce a BCR-ABL mutation, wherein the blast crisis CML cell line is a KCL-22 cell line;
- maintaining a culture of the imatinib-treated cell line for about two to three weeks until the cell line relapses and repopulates the culture;
- and
- determining that the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation.
A culture model of chronic myelogenic leukemia (CML) acquired chemoresistant cells, the model generated by:
- contacting a blast crisis CML cell line, which has previously not been exposed to imatinab before, with a single dose of imatinib sufficient to induce a BCR-ABL mutation, wherein the blast crisis CML cell line is a KCL-22 cell line;
- maintaining a culture of the imatinib-treated cell line for a period of time until the cell line relapses and repopulates the culture;
- and
- determining that the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation.
Dependencies are inferred from the claim text.